Molecular Therapy: Methods & Clinical Development (Mar 2019)

A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing

  • Ang Li,
  • Ciaran M. Lee,
  • Ayrea E. Hurley,
  • Kelsey E. Jarrett,
  • Marco De Giorgi,
  • Weiqi Lu,
  • Karol S. Balderrama,
  • Alexandria M. Doerfler,
  • Harshavardhan Deshmukh,
  • Anirban Ray,
  • Gang Bao,
  • William R. Lagor

Journal volume & issue
Vol. 12
pp. 111 – 122

Abstract

Read online

Adeno-associated viral (AAV) vectors packaging the CRISPR-Cas9 system (AAV-CRISPR) can efficiently modify disease-relevant genes in somatic tissues with high efficiency. AAV vectors are a preferred delivery vehicle for tissue-directed gene therapy because of their ability to achieve sustained expression from largely non-integrating episomal genomes. However, for genome editizng applications, permanent expression of non-human proteins such as the bacterially derived Cas9 nuclease is undesirable. Methods are needed to achieve efficient genome editing in vivo, with controlled transient expression of CRISPR-Cas9. Here, we report a self-deleting AAV-CRISPR system that introduces insertion and deletion mutations into AAV episomes. We demonstrate that this system dramatically reduces the level of Staphylococcus aureus Cas9 protein, often greater than 79%, while achieving high rates of on-target editing in the liver. Off-target mutagenesis was not observed for the self-deleting Cas9 guide RNA at any of the predicted potential off-target sites examined. This system is efficient and versatile, as demonstrated by robust knockdown of liver-expressed proteins in vivo. This self-deleting AAV-CRISPR system is an important proof of concept that will help enable translation of liver-directed genome editing in humans. Keywords: CRISPR/Cas9, adeno-associated virus, AAV, in vivo delivery, self-deleting, somatic genome editing, liver, AAV-CRISPR, gene therapy